Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Analysts Offer Insights on Healthcare Companies: Novartis AG (Six Swiss: CH:NOVN), Carl Zeiss Meditec (GB:0DHC) and Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD)
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target Is AU$3.03
Ord Minnett Starts ImpediMed at Speculative Buy, Price Target Is AU$0.16
JPMorgan Upgrades Ansell to Overweight From Neutral, Price Target Is AU$29.20
Macquarie Upgrades Ansell to Outperform From Neutral, Price Target Is AU$28.15
JPMorgan Upgrades Fisher & Paykel Healthcare to Neutral From Underweight; Price Target Is NZ$24.00
Wilsons Downgrades Somnomed to Marketweight From Overweight; Price Target Is AU$0.45
Morgan Stanley Adjusts Cochlear's Price Target to AU$276 From AU$258, Keeps at Underweight
Morgan Stanley Adjusts Fisher & Paykel Healthcare's Price Target to AU$22.19 From AU$21.50, Keeps at Equalweight
Morgan Stanley Adjusts Resmed's Price Target to AU$31.80 From AU$28.60, Keeps at Overweight
Morgan Stanley Adjusts Ansell's Price Target to AU$24.14 From AU$25.38, Keeps at Equalweight
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target Is AU$31
Jarden Research Adjusts Cochlear's Price Target to AU$244.35 From AU$237.17, Keeps at Neutral
Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral
Morgan Stanley Upgrades Resmed to Overweight From Equalweight, Adjusts Price Target to AU$26 From AU$27.70
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Teladoc (TDOC) and Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) and Zur Rose Group AG (Six Swiss: CH:DOCM)